BioSpace News Archive

Croda Pharma and BSI announced that they have entered into a strategic collaboration agreement to support the sustainable sourcing of pharmaceutical grade adjuvant QS-21, a potent component of adjuvant systems.

Terns Pharmaceuticals, Inc. announced that new preclinical data from a transgenic mouse model evaluating TERN-601, a novel oral GLP-1R agonist, has been accepted for poster presentation at the American Diabetes Association’s 83rd Annual Scientific Sessions taking place June 23-26, 2023 in San Diego, California.

Guardant Health, Inc., a leading precision oncology company, announced that it has commenced an underwritten public offering of $250.0 million of its common stock.

Icosavax, Inc. (Nasdaq: ICVX) today announced positive topline interim results from its Phase 1 clinical trial of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults.

Icosavax, Inc. announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 8,369,754 shares of its common stock at a purchase price of $8.10 per share.

Today, the U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older.

Agile Therapeutics, Inc., a women’s healthcare company, announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $3.9551 per share and accompanying warrants.

Guardant Health, Inc., a leading precision oncology company, announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions.

Thousand Oaks Biologics Inc. and GeneQuantum Healthcare Co., Ltd. are pleased to announce that they have formed a strategic partnership focusing on the CMC development of ADC products with a core conjugation technology for more stable drug candidates.

ANGLE plc, a world-leading liquid biopsy company announces that Garth Selvey has informed the Board of his intention to retire and leave ANGLE at the publication of the 2023 Interims in September.